An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Public ClinicalTrials.gov record NCT04201262. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Study identification
- NCT ID
- NCT04201262
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 58 participants
Conditions and interventions
Interventions
- Ravulizumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 8, 2019
- Primary completion
- Mar 14, 2022
- Completion
- Oct 30, 2024
- Last update posted
- Oct 13, 2025
2019 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Fort Collins | Colorado | 80528 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | Jackson | Mississippi | 39216 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Cincinnati | Ohio | 45219 | — |
| Research Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04201262, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04201262 live on ClinicalTrials.gov.